Achieving a prominent position in the treatment of dermatological and chronic-degenerative pathologies, discovering and developing innovative solutions that are easily accessible to patients.
Becoming a recognised and respected company that provides practical and easy to apply responses to those seeking to improve their health and well-being.
Ensuring constant investment in our research and development activities so as to offer outstanding therapeutic solutions, including by means of partnerships.
Contributing to the progress of medicine, providing the right answers to the needs of doctors and guaranteeing ethical behaviour in our research and development, production, communication and sales activities.
Founded in 2009 but heir to an intense research and development activity since 2004, Freia Farmaceutici has established a world leadership position in developing plant-based therapeutic solutions for human health through its effective drug discovery and development processes, its intellectual property portfolio and regulatory and manufacturing expertise.
Particularly, over the years Freia has developed a specific knowledge about hemp plants.
Today Freia possesses, among few pharmaceutical companies in the world, an extensive knowledge as research, development, design, formulation of this plant in the agronomic, extraction and human health product manufacturing fields. All Freia’s activities create and aim to create new hemp varieties and hemp-derived products, free from THC and CBD. Over the years, Freia has pursued a precise strategy in intellectual property management and production, based on an integrated management of all components: proprietary raw materials, patents, trademarks and clinical evidence.
For its innovative business idea, Freia Farmaceutici was funded by Lombardy Region through SEED Fund – a Revolving Fund for financing new innovative Lombard companies.
Freia Farmaceutici has been awarded with the Seal of Excellence - Phase II by the European Commission under Horizon 2020 program. First company in Europe, Freia received, through Horizon 2020 program, a grant from the European Commission to finance the development of an innovative line of hemp-based products to support patients suffering from cachexia.
For its research vocation, Freia has been recognized as Innovative SME since 2017 and registered in the specific list of Italian innovative companies.
Freia Farmaceutici in 2016 signed a commercial partnership with Rohto Pharmaceutical, a leading Japanese pharmaceutical company founded at the end of the 19th century, leader in dermocosmetics and ophthalmology both in Asia and in America. Promedial is their dermocosmetic line for sensitive skin with a high formulation quality with particular attention to consumer needs. Rohto Pharmaceutical has grown over the years in numerous sectors with the aim of providing useful and comprehensive health and beauty solutions.
Some figures regarding Rohto Pharmaceutical:
Always committed with significant resources in research and development, in 2006 Rohto inaugurated the Kyoto Research Village, a reference point for international doctorates and advanced research projects in which companies from all over the world can operate. Today Rohto is engaged in stem cell research for the development of therapeutic solutions in oncology and neurodegenerative therapeutic areas.
Rohto Pharmaceutical has chosen Freia Farmaceutici as partner to exploit the Italian market, first country for expansion in Europe.
Today Promedial is the only Japanese brand present in pharmacies and, thanks to a network of scientific representatives, it is also known among clinical practitioners, in particular aesthetic doctors, who can know the benefits of Promedial products use within their clinical protocols.